Precision For Medicine’s Post

𝐌𝐚𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐈𝐦𝐦𝐮𝐧𝐨𝐡𝐢𝐬𝐭𝐨𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲(𝐈𝐇𝐂) 𝐟𝐨𝐫 𝐓𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Are you seeking to optimize your use of IHC in translational research? Our webinar provides an in-depth exploration of IHC, covering everything from biomarker identification to assay development. Join us to learn how IHC can elevate your research and expedite your path to clinical trials. Live Q&A to follow. https://hubs.ly/Q02G10Pg0 #biomarkers #clinicaltrials

The first meeting of our new Rethinking Bioanalysis series was amazing! If you missed it, you can download it here.

Did you know that titers can be deceiving, and signal-to-noise (S/N) is often BETTER than titer for characterizing immunogenicity responses? Learn how using S/N can turn confusion into clarity in the next Rethinking Bioanalysis discussion on June 27 at Noon ET: “Immunogenicity Assays Are Biomarker Assays: Case Study - A Journey From Consternation to Clarity,” with Dr. Lauren Stevenson, Dr. Devangi Mehta, and the Immunologix Translational Sciences team. Register here: https://lnkd.in/g3GcDqVD #Bioanalysis #Immunogenicity #RethinkingBioanalysis #TranslationalSciences

Join this CAP complimentary webinar to explore the complexities of biomarker testing in oncology. Discover case studies where different modalities yield conflicting results. We will delve into various testing methods, including immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS), and their limitations to better address challenges in diagnosis and treatment decisions. #CAP #PrecisionMedicine

🤝🏻 We have successfully completed our collaboration with the Welch research group at The Babraham Institute to evaluate lead compounds predicted to bind a pro-inflammatory protein identified in our pilot studies. The project was funded by the UKRI-BBSRC Campus Innovation Award (CIA), via the Babraham Research Campus Collaboration Fund in October 2023. The collaboration demonstrates that new disease-specific targets identified in our trial have the potential to be modifiable by small molecule drugs—opening new opportunities for a precision medicine approach to heart disease. We are now evaluating the target in our ongoing BIOPATTERN trial and, if validated, further development will be pursued. Read more ➡ https://rb.gy/6b1o61 #CoronaryArteryDisease #Collaboration #ClinicalTrial #PrecisionMedicine #HeartDisease

We are excited to participate in the first BioLabs European Investor Day in Paris! 🌎 🇫🇷 Europe’s top biotech startups and the most active European and international life science investors will come together on March 19th to advance medicine. We are honored to present our contributions to the earlier and precise diagnosis of Acute Kidney Injury (AKI). The Sciomics scioAKI project has identified promising early biomarker combinations for perioperative AKI with a very strong diagnostic performance. Based on these results, a new spin-off will be dedicated to the development of a reliable and easy-to-use test for the early diagnosis of AKI in a clinical setting. Saving kidneys, saving lives! 🏥 #BioLabsEuropeanInvestorDay #precisionmedicine #acutekidneyinjury #proteomics

The journey from biomarker discovery to clinical trial assay is crucial for precision medicine. Immunohistochemistry (IHC) plays a vital role in this process. Learn about the key factors in IHC assay development and how it supports better clinical outcomes in our latest blog. https://hubs.ly/Q02NzXf40 #biomarkers #clinicaltrials #precisionmedicine #immunohistochemistry

Poll Results Are In! Thank you to everyone who voted on our poll - 'the most challenging aspect of implementing biomarkers in clinical trials.' The majority of you highlighted "Identifying Biomarkers" as a significant hurdle. Intrigued by this topic? Join the conversation at the 2nd Annual Clinical Trials Festival Asia Conference, where experts will delve into overcoming challenges and unlocking the potential of biomarkers in clinical research. [https://lnkd.in/gzPaTPMN] Don't miss the chance to gain valuable insights, network with industry professionals, and stay at the forefront of clinical trials advancements. Save the date! 🗓️ #ClinicalTrials #Biomarkers #ClinicalResearch #CTFA2024

Detecting biomarker interactions in cells / tissue? Within 10 nm? That is exactly what HAWK Biosystems achieved with their FLIM microscopy platform "Violet 3.0" - Great webinar showing why that is crucial for things like: 👉Understanding variability in response to pre/clinical #trials 👉Overcoming #immunohistochemistry limitations 👉Deeper biological #pathway research 👉 Moving from #biomarker concentration to biomarker function - better prediction of response to therapy #immunooncology My DMs are open to discuss specific applications 🔬 https://lnkd.in/dj6-9YDm

🌟 Lab Showcase Series, Episode 7: Boshart Lab 🌟 In our latest installment of the Lab Showcase Series, we feature the pioneering research of the Boshart Lab at Ludwig-Maximilians-Universität München (LMU Munich) ! 🧬✨ Under the leadership of Prof. Dr. Michael Boshart , this lab delves into the intricate world of cell signaling in development and the host interaction of protozoan parasites. 🔍 Key Research Highlights: 🔬 Host-Pathogen Adaptation: The Boshart Lab investigates how trypanosomes and Leishmania adapt to host environments and evade immune defenses. 🦠🛡️ 📶 cAMP Signaling: This lab explores the role of cAMP's role in parasite communication and immune evasion. 🧪🧬 🌡️ Temperature-Induced Differentiation: The team examines how body temperature changes trigger parasite differentiation via protein kinase A. 🔥🔄 💊 Drug Development: By identifying unique parasite signaling pathways as drug targets, the Boshart lab focuses on development of specific agonists and inhibitors. 💉🔬 For more insights into their groundbreaking work, visit: _🔗 Boshart Lab Homepage: https://lnkd.in/gQdx3v-Q Credits: Poster: Smrutimayee Prusty Content: Md Rashid Alam #LabShowcaseSeries #NGSF #BoshartLab #LMUMunich #ProtozoanParasites #research #opportunities